^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Trailblaze Pharos™

    Company:
    Roche
    Type:
    CE Marked
    Related tests:
    Trailblaze Pharos™ is a multiplex next-generation sequencing (NGS) based assay for the qualitative detection of fusions in the NTRK1/2/3, ROS1, or ALK genes in the RNA from formalin-fixed paraffin-embedded (FFPE) human solid tumor tissue. The assay is intended to be used as an aid in selecting patients, including those who are treatment-naïve, with solid tumors that harbor a gene rearrangement in NTRK1/2/3, ROS1, or ALK
    Cancer:
    Solid Tumor
    Gene:
    ALK (Anaplastic lymphoma kinase), NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1), NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2), NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3), ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    Drug:
    Rozlytrek (entrectinib)
    Method:
    Next-Generation Sequencing
    Approvals
    Date
    Cancer
    Gene
    Drug
    By
    11/15/16
    ST
    NTRK1
    CE
    NTRK2
    NTRK3
    ROS1
    ALK
    Confirmatory trial(s)
    STARTRK-2
    ,
    NCT02568267
    |
    Lancet Oncol